Pharmacology of Ethanol

Introduction/Overview

Ethanol, or ethyl alcohol, is a simple two-carbon alcohol (CH₃CH₂OH) that represents one of the most widely consumed psychoactive substances globally. Its use spans recreational, cultural, ritualistic, and, to a limited extent, therapeutic contexts. The pharmacology of ethanol is complex, involving non-specific interactions with multiple neuronal systems and a metabolism that follows non-linear kinetics. Understanding this pharmacology is fundamental for medical and pharmacy students, as ethanol consumption interacts with a vast array of pathological conditions and pharmacotherapies. Ethanol use disorder constitutes a major public health challenge, associated with significant morbidity, mortality, and socioeconomic burden. Consequently, a thorough grasp of its pharmacological principles is essential for safe clinical practice, enabling effective patient counseling, management of intoxication and withdrawal, and recognition of potential drug interactions.

Learning Objectives

• Describe the principal pharmacodynamic mechanisms of ethanol, including its effects on ligand-gated ion channels and intracellular signaling pathways.
• Explain the non-linear (zero-order) pharmacokinetics of ethanol, detailing the pathways of absorption, distribution, metabolism, and excretion.
• Identify the approved therapeutic applications of ethanol and its role in the management of alcohol use disorder.
• Analyze the spectrum of adverse effects associated with acute and chronic ethanol consumption, from neurological impairment to multi-organ toxicity.
• Evaluate significant drug interactions involving ethanol and apply special considerations for its use in vulnerable populations.

Classification

Ethanol is chemically classified as a primary aliphatic alcohol. From a pharmacological perspective, it is primarily categorized as a central nervous system (CNS) depressant, sharing this broad classification with agents such as barbiturates, benzodiazepines, and general anesthetics. However, its mechanism is distinct and more generalized than these receptor-specific drugs. Ethanol is not typically classified within a standard therapeutic drug class due to its limited medicinal indications. In clinical toxicology and substance use disorders, it is recognized as the prototypical agent for alcohol use disorder. Medicinally, it is also employed as an antiseptic and disinfectant, classified topically as a germicidal agent. When used as an antidote, it acts as a competitive substrate for alcohol dehydrogenase in the treatment of methanol or ethylene glycol poisoning.

Mechanism of Action

The pharmacodynamic actions of ethanol are pleiotropic, arising from its ability to perturb the lipid bilayer of neuronal membranes and directly interact with specific protein targets. Unlike most drugs with high-affinity binding to discrete receptors, ethanol exerts its effects at millimolar concentrations, influencing a wide array of neurotransmitter systems.

Effects on Neurotransmitter Systems and Ion Channels

The primary CNS effects are mediated through enhancement of inhibitory neurotransmission and suppression of excitatory neurotransmission. Ethanol potentiates the action of gamma-aminobutyric acid (GABA) at GABA_A receptors. This potentiation is believed to occur through binding sites distinct from those of benzodiazepines or barbiturates, possibly at interfacial sites between receptor subunits. This action increases chloride ion influx, leading to neuronal hyperpolarization and CNS depression. Concurrently, ethanol inhibits the function of N-methyl-D-aspartate (NMDA) subtype of glutamate receptors. This antagonism reduces calcium ion influx and attenuates excitatory signaling, contributing to cognitive impairment, memory disruption, and, with chronic use, neuroadaptive changes.

Ethanol also influences other ligand-gated ion channels. It inhibits neuronal nicotinic acetylcholine receptors and activates certain subtypes of serotonin receptors (5-HT₃). Furthermore, it stimulates the release of endogenous opioids and dopamine in the mesolimbic pathway, particularly in the nucleus accumbens. This dopaminergic activation in the reward circuitry is a critical component underlying the reinforcing properties and addictive potential of ethanol.

Intracellular Signaling and Gene Expression

Beyond immediate receptor effects, ethanol modulates intracellular second messenger systems. It can inhibit voltage-gated calcium channels and alter the activity of adenylyl cyclase, protein kinase A (PKA), and protein kinase C (PKC). With chronic exposure, these perturbations trigger compensatory neuroadaptations. Upregulation of NMDA receptors and downregulation of GABA_A receptor function are hallmarks of tolerance and physical dependence. These changes also involve alterations in gene expression mediated by transcription factors such as cAMP response element-binding protein (CREB) and ΔFosB, leading to long-term neuronal plasticity associated with addiction.

Pharmacokinetics

The disposition of ethanol in the body is characterized by rapid absorption, distribution according to body water content, capacity-limited metabolism, and minimal renal excretion of the unchanged compound.

Absorption

Absorption occurs primarily via passive diffusion across mucous membranes of the gastrointestinal tract, with approximately 20% absorbed in the stomach and 80% in the small intestine. The rate of absorption is influenced by several factors. Gastric emptying time is a major determinant; absorption is slowed by the presence of food, particularly high-fat or high-protein meals, which delay gastric emptying. Conversely, carbonated beverages may accelerate absorption. The concentration of the alcoholic beverage also affects absorption, with very high concentrations (>40%) causing pyloric spasm and delaying gastric emptying. Under fasting conditions, peak plasma concentrations (C_max) are typically reached within 30 to 60 minutes.

Distribution

Ethanol is a small, hydrophilic molecule that distributes readily into total body water. Its volume of distribution (V_d) is approximately 0.5–0.7 L/kg, correlating closely with lean body mass and water content. This property explains the generally higher blood ethanol concentrations achieved in women compared to men after equivalent doses per body weight, as women typically have a higher percentage of body fat and lower total body water. Ethanol freely crosses the blood-brain barrier and the placenta, and is distributed into breast milk.

Metabolism

Over 90% of ingested ethanol is metabolized hepatically, with the remainder excreted unchanged in breath, urine, and sweat. Hepatic metabolism follows Michaelis-Menten kinetics, shifting from first-order at low concentrations to zero-order at higher, clinically relevant concentrations. This occurs because the primary metabolic enzyme becomes saturated.

The major pathway involves two sequential oxidative steps:

1. Oxidation to Acetaldehyde: Catalyzed primarily by cytosolic alcohol dehydrogenase (ADH). This enzyme uses nicotinamide adenine dinucleotide (NAD⁺) as a cofactor, reducing it to NADH. The reaction is: Ethanol + NAD⁺ → Acetaldehyde + NADH + H⁺. A minor pathway, the microsomal ethanol-oxidizing system (MEOS) involving cytochrome P450 2E1 (CYP2E1), becomes significant with chronic high intake, contributing to metabolic tolerance and increased hepatotoxicity.
2. Oxidation to Acetate: Acetaldehyde, a highly reactive and toxic metabolite, is rapidly oxidized to acetate by mitochondrial aldehyde dehydrogenase (ALDH), primarily the ALDH2 isoform. This reaction also uses NAD⁺, producing more NADH: Acetaldehyde + NAD⁺ + H₂O → Acetate + NADH + H⁺.

Acetate is subsequently converted to acetyl-CoA in peripheral tissues and enters the Krebs cycle or other metabolic pathways. The shift in hepatic redox state (increased NADH/NAD⁺ ratio) during metabolism drives several metabolic consequences, including hypoglycemia, hyperlactatemia, and fatty acid synthesis.

Excretion and Elimination Kinetics

A small fraction (2–10%) of ethanol is excreted unchanged by the lungs and kidneys. The pulmonary excretion forms the basis for breathalyzer tests. The elimination of ethanol is typically described by zero-order kinetics at blood concentrations above approximately 10 mg/dL. The average elimination rate is 15–20 mg/dL per hour (or approximately 7–10 g of ethanol per hour for a 70 kg adult), though this can vary widely based on genetic factors, chronic use, and liver function. The half-life (t_1/2) is therefore concentration-dependent and not a fixed value. The zero-order rate constant (k₀) is often used, where the decline in plasma concentration is linear: C(t) = C₀ – k₀t.

Therapeutic Uses/Clinical Applications

The therapeutic applications of ethanol are limited but important in specific clinical scenarios.

Approved Indications

• Topical Antiseptic: Ethanol (typically 70% v/v) is a widely used disinfectant for skin prior to injections or surgical procedures and for disinfecting surfaces and instruments. Its bactericidal effect is achieved by protein denaturation.
• Antidote for Methanol and Ethylene Glycol Poisoning: Ethanol is a competitive substrate for ADH, with an affinity approximately 10–20 times greater than methanol. By saturating ADH, ethanol prevents the formation of toxic metabolites (formic acid from methanol, glycolic and oxalic acids from ethylene glycol). It is administered intravenously or orally to maintain a target blood ethanol concentration of 100–150 mg/dL. Fomepizole, a direct ADH inhibitor, has largely replaced ethanol for this indication due to its easier dosing and superior safety profile.
• Treatment of Alcohol Use Disorder: While ethanol itself is not a treatment, its pharmacology underpills several pharmacotherapies. Disulfiram, acamprosate, and naltrexone are FDA-approved for maintaining abstinence. Disulfiram inhibits ALDH, causing an accumulation of acetaldehyde upon ethanol ingestion, producing a highly aversive reaction (flushing, tachycardia, nausea).

Off-Label and Historical Uses

Historically, ethanol was used as a sedative-hypnotic, analgesic, and to delay premature labor (tocolysis), but these uses are obsolete due to the availability of safer and more effective agents. It is sometimes used as a solvent for various medicinal compounds.

Adverse Effects

The adverse effect profile of ethanol is extensive, affecting nearly every organ system. Effects are dichotomized into acute (intoxication) and chronic consequences.

Acute Adverse Effects (Intoxication)

The CNS effects follow a dose-dependent continuum. At low blood alcohol concentrations (BAC: 20–50 mg/dL), disinhibition, euphoria, and mild motor incoordination may occur. At moderate levels (50–150 mg/dL), slurred speech, ataxia, impaired judgment, and emotional lability are evident. Severe intoxication (BAC > 250 mg/dL) leads to stupor, coma, respiratory depression, hypothermia, and potentially death from respiratory arrest or aspiration. Cardiovascular effects include peripheral vasodilation (causing flushing and heat loss) and a mild increase in heart rate. Gastrointestinal effects include acute gastritis and nausea.

Chronic Adverse Effects

• Neurological: Tolerance, physical dependence, and withdrawal syndrome (tremors, autonomic hyperactivity, hallucinations, seizures, delirium tremens). Wernicke-Korsakoff syndrome (due to thiamine deficiency), cerebellar degeneration, peripheral neuropathy, and cerebral atrophy.
• Hepatic: Fatty liver (steatosis), alcoholic hepatitis, fibrosis, and cirrhosis. Cirrhosis leads to portal hypertension, ascites, and hepatic encephalopathy.
• Gastrointestinal: Chronic pancreatitis, gastritis, esophageal varices, and malnutrition.
• Cardiovascular: Cardiomyopathy (dilated), arrhythmias (e.g., atrial fibrillation – “holiday heart syndrome”), hypertension.
• Malignancy: Increased risk of cancers of the oropharynx, larynx, esophagus, liver, colon, and breast.
• Endocrine/Metabolic: Pseudo-Cushing’s syndrome, gonadal dysfunction (testicular atrophy, amenorrhea), osteoporosis, and electrolyte disturbances.
• Immune System: Suppressed immune function, increasing susceptibility to infections such as pneumonia and tuberculosis.

Fetal Alcohol Spectrum Disorders (FASD), with Fetal Alcohol Syndrome (FAS) being the most severe, result from prenatal exposure and are characterized by growth retardation, facial dysmorphology, and central nervous system abnormalities.

Drug Interactions

Ethanol participates in numerous pharmacokinetic and pharmacodynamic drug interactions, many of which are clinically significant.

Pharmacodynamic Interactions

Additive or synergistic CNS depression occurs with other sedative-hypnotics, including benzodiazepines, barbiturates, opioids, antipsychotics, and antidepressants. This combination significantly increases the risk of accidental overdose, respiratory depression, and death. Ethanol can also potentiate the hypotensive effects of antihypertensive medications and enhance the gastrointestinal bleeding risk associated with nonsteroidal anti-inflammatory drugs (NSAIDs) and anticoagulants like warfarin.

Pharmacokinetic Interactions

• Acute Ingestion: Can competitively inhibit the metabolism of other drugs that are substrates for ADH or CYP2E1, potentially increasing their plasma levels.
• Chronic Use: Induces hepatic CYP2E1 and, to a lesser extent, CYP3A4. This induction can increase the metabolic clearance and reduce the efficacy of drugs metabolized by these enzymes, such as warfarin (variable effect), phenytoin, and certain antiretroviral drugs. Conversely, upon cessation of drinking, the loss of enzyme induction can lead to unexpectedly high drug levels and toxicity.
• With Disulfiram-like Drugs: Several drugs (e.g., metronidazole, certain sulfonylureas, some cephalosporins like cefotetan) can inhibit ALDH, leading to an “acetaldehyde syndrome” similar to a disulfiram reaction if ethanol is consumed.

Contraindications

Absolute contraindications to ethanol consumption include pregnancy (due to risk of FASD), severe hepatic impairment (e.g., cirrhosis with decompensation), acute pancreatitis, and uncontrolled epilepsy. It is also contraindicated in individuals taking disulfiram or other medications with a disulfiram-like reaction potential. Relative contraindications include a history of alcohol use disorder, peptic ulcer disease, cardiomyopathy, and concurrent use of any medication with significant CNS depressant activity.

Special Considerations

Pregnancy and Lactation

Ethanol is a known human teratogen. There is no established safe level of consumption during pregnancy. It crosses the placenta freely, and fetal blood concentrations approximate maternal levels. The developing fetal brain is exquisitely sensitive to ethanol’s neurotoxic effects, which can cause lifelong cognitive, behavioral, and physical disabilities under the umbrella of FASD. Complete abstinence is recommended throughout pregnancy. Ethanol is also excreted into breast milk, with milk concentrations similar to maternal blood concentrations. It can cause sedation, poor feeding, and impaired motor development in the nursing infant. Mothers are advised to avoid breastfeeding for at least 2–3 hours per standard drink consumed to allow for ethanol clearance.

Pediatric and Geriatric Considerations

Pediatric exposures are typically accidental and can lead to severe hypoglycemia and profound CNS depression at lower doses compared to adults due to smaller body mass and immature metabolic pathways. In older adults, physiological changes alter ethanol pharmacokinetics and pharmacodynamics. An age-related increase in the ratio of body fat to water leads to a smaller volume of distribution and higher blood concentrations for a given dose. Reduced hepatic blood flow and possibly diminished ADH activity can slow elimination. Furthermore, increased CNS sensitivity renders older adults more susceptible to the cognitive impairing, sedative, and ataxic effects of ethanol, increasing fall risk. Polypharmacy in this population also elevates the potential for dangerous drug interactions.

Renal and Hepatic Impairment

Renal impairment has a minimal direct effect on ethanol clearance, as little is excreted unchanged. However, fluid and electrolyte imbalances associated with both renal disease and ethanol use can be exacerbated. Hepatic impairment is the critical consideration. In patients with significant liver disease (e.g., cirrhosis), the capacity to metabolize ethanol via ADH and ALDH is substantially reduced, leading to prolonged elimination and exaggerated pharmacological effects. The induction of CYP2E1 by chronic use can exacerbate oxidative stress and hepatocyte injury, accelerating the progression of liver disease. The use of ethanol is generally contraindicated in patients with advanced hepatic impairment.

Summary/Key Points

• Ethanol is a CNS depressant with multifaceted mechanisms, primarily enhancing GABAergic inhibition and suppressing glutamatergic (NMDA) excitation, while also activating mesolimbic dopamine reward pathways.
• Its pharmacokinetics are characterized by rapid absorption, distribution into total body water (V_d ≈ 0.6 L/kg), and capacity-limited (zero-order) hepatic metabolism primarily via alcohol dehydrogenase (ADH) and aldehyde dehydrogenase (ALDH).
• Therapeutic uses are limited to topical antisepsis and as a historical antidote for methanol/ethylene glycol poisoning, largely supplanted by fomepizole.
• Acute toxicity manifests as dose-related CNS depression, while chronic use leads to tolerance, dependence, and multi-organ damage, notably affecting the liver, pancreas, cardiovascular system, and brain, and is a significant risk factor for several cancers.
• Ethanol engages in dangerous pharmacodynamic interactions with other CNS depressants and can induce cytochrome P450 enzymes (CYP2E1), altering the metabolism of numerous drugs.
• Special populations require heightened caution: ethanol is a potent teratogen (FASD), older adults have increased sensitivity, and hepatic impairment drastically reduces metabolic clearance and increases toxicity.

Clinical Pearls

• The rate of ethanol elimination is relatively constant (≈20 mg/dL/h) and independent of concentration within the intoxicated range; calculating the time to sobriety requires a linear, not exponential, estimation.
• The disulfiram reaction (flushing, tachycardia, nausea) is caused by acetaldehyde accumulation and can be precipitated by several common medications beyond disulfiram itself, including metronidazole.
• In managing suspected methanol or ethylene glycol ingestion, initiating therapy with fomepizole or ethanol should not be delayed while awaiting confirmatory laboratory levels.
• Chronic ethanol consumption can induce CYP2E1, potentially reducing the efficacy of drugs like warfarin; however, acute intoxication or concomitant liver disease can have the opposite effect, making anticoagulant management particularly challenging.
• Thiamine (vitamin B1) should be administered empirically to all patients presenting with severe alcohol intoxication or withdrawal to prevent or treat Wernicke’s encephalopathy.

References

1. Whalen K, Finkel R, Panavelil TA. Lippincott Illustrated Reviews: Pharmacology. 7th ed. Philadelphia: Wolters Kluwer; 2019.
2. Rang HP, Ritter JM, Flower RJ, Henderson G. Rang & Dale's Pharmacology. 9th ed. Edinburgh: Elsevier; 2020.
3. Trevor AJ, Katzung BG, Kruidering-Hall M. Katzung & Trevor's Pharmacology: Examination & Board Review. 13th ed. New York: McGraw-Hill Education; 2022.
4. Katzung BG, Vanderah TW. Basic & Clinical Pharmacology. 15th ed. New York: McGraw-Hill Education; 2021.
5. Golan DE, Armstrong EJ, Armstrong AW. Principles of Pharmacology: The Pathophysiologic Basis of Drug Therapy. 4th ed. Philadelphia: Wolters Kluwer; 2017.
6. Brunton LL, Hilal-Dandan R, Knollmann BC. Goodman & Gilman's The Pharmacological Basis of Therapeutics. 14th ed. New York: McGraw-Hill Education; 2023.
7. Rang HP, Ritter JM, Flower RJ, Henderson G. Rang & Dale's Pharmacology. 9th ed. Edinburgh: Elsevier; 2020.
8. Whalen K, Finkel R, Panavelil TA. Lippincott Illustrated Reviews: Pharmacology. 7th ed. Philadelphia: Wolters Kluwer; 2019.